Recent data from VOYAGER PAD showed no association between drug-coated device (DCD) use and mortality. Given the absence of a safety signal, the current analysis examined the potential benefit of DCD versus non-DCD treatment for reducing limb outcomes. Connie Hess (University of Colorado, Aurora, USA) presented the most recent findings in a late-breaking data session at this year’s Vascular Interventional Advances conference (VIVA 2020; 6–8 November, virtual), reporting no excess mortality and improved limb outcomes with drug-coated device use in peripheral arterial disease (PAD).
Hess noted that patency remains a challenge, and that drug-coated devices are associated with a reduction in clinically-driven unplanned index limb revascularisation. However, she relayed that rivaroxaban 2.5mg twice daily plus aspirin reduces this risk, in addition to reducing major adverse events of the heart, limb, and brain, irrespective of device type. “These observations suggest that a ‘pharmaco-invasive’ approach combining innovative devices with effective medical therapy may optimise outcomes in PAD,” she told the VIVA audience.
The co-primary outcomes for this analysis were unplanned index limb revascularisation and major adverse limb events (MALE), defined as acute limb ischemia or major amputation of vascular cause. As drug-coated use was not randomised, inverse probability treatment weighting was used to account for known confounders.
Hess detailed that use of a drug-coated device was associated with a significant 16% reduction in relative risk of clinically-driven unplanned index limb revascularisation (hazard ratio [HR] 0.84, 95% confidence interval [CI] 0.76–0.92) but was not associated with a reduction in MALE (HR 1.08, 95% CI 0.9–1.3).